Morgan Stanley lowered the firm’s price target on CME Group (CME) to $303 from $304 and keeps an Overweight rating on the shares. Record volumes in Q2 showcased broad based strength, says the analyst, who sees macro conditions supporting volumes growth better than expectations as customers face greater need to manage and hedge risk.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group downgraded to Neutral from Buy at UBS
- CME Group price target raised to $303 from $300 at Oppenheimer
- Positive Outlook for CME Group Driven by Risk Management Demand and Strong Financial Position
- CME Group price target lowered to $298 from $299 at Barclays
- CME Group Inc. Reports Record Q2 2025 Earnings